不过，也有少量药物调低价格。约9种药物将降价，其中包括勃林格殷格翰（Boehringer Ingelheim）糖尿病药物Jardiance及相关三款药 物，降幅超过40%。Jardiance是2026年美国政府为65岁及以上医保计划谈判降价的10款药物之一，两家公司将该药价格下调约三分之 二。 美国患者目前支付的处方药费用远高于其他发达国家，往往是其他国家的近三倍。特朗普一直要求药企将美国药价降至类似富裕国家的 水平。然而，即便特朗普已与14家药企达成部分药物价格协议，这些公司仍计划在1月1日提高部分药物价格。涉及公司包括辉瑞 （Pfizer）、赛诺菲（Sanofi）、勃林格殷格翰、诺华（Novartis）和葛兰素史克（GSK）。 整理 | GLP1减重宝典内容团队 尽管特朗普政府一直施压药企降低药价，但美国制药公司计划在2026年提高至少350种处方药的价格，其中包括针对新冠、呼吸道合胞 病毒（RSV）和带状疱疹的疫苗，以及抗癌重磅药物伊布替尼（Ibrance）。 与去年同期相比，今年的涨价药品数量有所增加——去年同期约为250种。今年的涨幅中位数约为4%，与2025年持平。这些价格调整仅 指药品标价，不包 ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on certain treatments for the government’s Medicaid program and for cash-pa ...

美国制药商计划在2026年提高至少350种品牌药物的价格，尽管特朗普政府正在施压要求降价。这一提 价规模较去年同期的250多种药物有所扩大，中位涨幅约为4%，与2025年持平。 辉瑞宣布的药品提价数量最多，约80种不同药物将涨价，包括抗癌药Ibrance、偏头痛药物Nurtec和新冠 治疗药物Paxlovid，以及吗啡和氢吗啡酮等医院用药。 涉及提价的药物包括新冠、呼吸道合胞病毒和带状疱疹疫苗，以及重磅抗癌药Ibrance等。据医疗研究机 构3 Axis Advisors独家提供的数据，辉瑞、赛诺菲、勃林格殷格翰、诺华和葛兰素史克等14家与特朗普 政府就部分药品价格达成协议的药企，也计划在1月1日上调部分药物价格。 美国患者目前支付的处方药价格远高于其他发达国家，通常是后者的近三倍。特朗普一直在向药企施 压，要求将价格降至与其他富裕国家相近的水平。 这些提价不反映给药品福利管理公司的返点和其他折扣。波士顿布莱根妇女医院的卫生政策研究员 Benjamin Rome博士表示，这些协议"被宣传为变革性的，但实际上只是在边缘上做文章，并未真正解 决美国处方药高价的根本原因"。 辉瑞领涨，部分药物涨幅超四倍 辉瑞大多数 ...

智通财经APP获悉，据医疗研究公司3 Axis Advisors独家提供的数据，制药商计划提高至少350种品牌药 在美国的价格，其中包括针对COVID、呼吸道合胞病毒和带状疱疹的疫苗，以及重磅癌症治疗药物 Ibrance。此举正值特朗普政府向其施压要求降价之际。 Jardiance是美国政府为针对65岁及以上人群的医疗保险计划在2026年进行价格谈判并成功降价的10种药 物之一。根据谈判结果，Boehringer和礼来将该药价格削减了三分之二。 与去年同期相比，2026年的计划涨价药品数量有所增加，去年此时药企公布了250多种药品的提价计 划。今年的价格涨幅中位数约为4%，与2025年持平。 目前美国患者支付的处方药价格远高于其他国家，通常是其他发达国家的近三倍。特朗普一直向制药商 施压，要求其将价格降至与类似富裕国家患者支付水平相当。 这些涨幅未反映对药品福利管理商等的回扣或其他折扣。 药企亦下调部分药品价格 制药商还计划下调约9种药品的目录价格。其中包括Boehringer Ingelheim的糖尿病药物Jardiance及其三 种相关疗法降价超40%。 共同销售Jardiance的Boehringer ...

Core Insights - Pfizer anticipates a significant revenue decline due to the loss of exclusivity for key products between 2026 and 2030, including Eliquis, Vyndaqel, Ibrance, Xeljanz, and Xtandi, all facing patent expirations [1][9] - The company has bolstered its R&D pipeline through mergers and acquisitions, successful data readouts, and pivotal program initiations, positioning itself for sustainable growth post-LOE [1][7] Oncology Pipeline - Pfizer has advanced its oncology pipeline with several candidates in late-stage development, including vepdegestrant for ER+/HER2- metastatic breast cancer, atirmociclib for HR+/HER2- metastatic breast cancer, and sigvotatug vedotin for metastatic non-small cell lung cancer [2] - By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio [4] Non-Oncology Developments - In non-oncology areas, Pfizer is developing an mRNA flu/COVID combination vaccine and osivelotor for sickle cell disease, both in late-stage development [4] - The company is also expanding the labels of approved products like Padcev, which was recently approved by the FDA in combination with Merck's Keytruda for specific bladder cancer patients [5] Obesity Market Expansion - Pfizer is strengthening its presence in the obesity market, currently dominated by Eli Lilly and Novo Nordisk, through the $10 billion acquisition of Metsera and the in-licensing of YP05002, an oral GLP-1 receptor agonist [6] - The Metsera acquisition added four novel clinical-stage programs for obesity, expected to generate billions in peak sales [6] Competitive Landscape - Pfizer faces revenue headwinds from patent expirations but is positioned for long-term growth through its expanding late-stage pipeline in oncology and investments in obesity, vaccines, and rare diseases [7] - The oncology market is competitive, with major players like AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers also focusing on oncology sales [10][11][12][13] Financial Performance - Pfizer's stock has declined 7% over the past year, while the industry has seen a 16% increase [14] - The company's shares are trading at a forward price/earnings ratio of 8.18, below the industry average of 17.40 and its own 5-year mean of 10.39, indicating attractive valuation [16] - The Zacks Consensus Estimate for 2025 earnings has increased slightly to $3.10 per share, while the estimate for 2026 has decreased to $3.04 per share [18]

Core Insights - Pfizer's stock has declined approximately 3% this week following the announcement of its financial guidance for 2026, which did not meet investor expectations [1] Financial Guidance - Pfizer anticipates total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting modest growth from the revised 2025 revenue expectation of around $62 billion, primarily due to lower revenues from COVID products and the impending patent cliff [2] - The company expects adjusted earnings per share in the range of $2.80 to $3.00 for 2026, a decline from the 2025 expected range of $3.00 to $3.15, influenced by the dilutive impact of recent deals and lower COVID revenues [3] Oncology Segment - Pfizer holds a strong position in oncology, with oncology sales accounting for approximately 28% of total revenues, which have increased by 7% in the first nine months of 2025 [4][5] - The company is advancing its oncology pipeline and expects to have eight or more blockbuster oncology medicines by 2030 [5] Product Development and Acquisitions - Pfizer is focusing on expanding its product labels and has in-licensed rights for new oncology treatments, including a dual PD-1 and VEGF inhibitor [6][7] - The company has reduced its dependence on COVID-related revenues, with non-COVID operational revenues improving due to key products and new acquisitions, which are expected to deliver double-digit growth in 2026 [8][9] Challenges and Headwinds - Pfizer is facing a significant revenue impact from the loss of exclusivity for several key products between 2026 and 2030, which is projected to reduce sales by approximately $1.5 billion in 2026 [15] - The company is also experiencing lower sales of COVID products due to decreased vaccination and infection rates, with expected COVID revenues around $5 billion in 2026, down from $6.5 billion in 2025 [12][14] Stock Performance and Valuation - Pfizer's stock has underperformed compared to the industry and the S&P 500, losing 4.9% year-to-date [17] - The stock is currently trading at a price/earnings ratio of 8.04, significantly lower than the industry average of 17.11 and its five-year mean of 10.41, indicating potential attractiveness for investors [20] Future Outlook - Despite current challenges, Pfizer's key drugs and new product launches are expected to help offset losses from patent expirations, with anticipated cost savings of $7.7 billion by the end of 2027 [26] - The company is viewed as a hold in investment portfolios as it rebuilds its pipeline in oncology and obesity, which could drive growth from 2029 onwards [27]

Core Insights - Novo Nordisk (NVO) and Pfizer (PFE) are leading pharmaceutical companies in distinct therapeutic areas, with NVO dominating the GLP-1 market and PFE traditionally strong in oncology [1][2] - Pfizer's recent acquisition of Metsera marks its re-entry into the obesity market, intensifying competition with Novo Nordisk [2][3] Novo Nordisk (NVO) - NVO holds a 59% global market share in the GLP-1 space, driven by its semaglutide products: Ozempic, Rybelsus, and Wegovy [5] - The company is expanding its manufacturing capacity and pursuing new indications for semaglutide, including cardiovascular benefits [6][7] - NVO is facing challenges with weaker sales of Ozempic and Wegovy, leading to a guidance cut and a restructuring program aimed at saving DKK 8 billion annually by 2026 [12][30] Pfizer (PFE) - PFE's oncology revenues have increased by 7% year-to-date, bolstered by the acquisition of Seagen and strong performance from key products [13][14] - The Metsera acquisition adds four clinical obesity programs to PFE's pipeline, enhancing its position in the obesity treatment market [16] - PFE is implementing cost reduction initiatives expected to save $7.7 billion by 2027, alongside a strong late-stage pipeline and a dividend yield of around 7% [15][32] Financial Estimates - The Zacks Consensus Estimate for NVO's 2025 sales and EPS indicates a year-over-year increase of approximately 14% and 9%, respectively [20] - In contrast, PFE's 2025 sales are expected to decrease by 1.1%, while EPS is projected to increase by 1% [23] Stock Performance and Valuation - Year-to-date, NVO shares have declined by 43.4%, while PFE shares have lost 3.1%, against an industry gain of 19% [26] - NVO trades at a higher price/earnings ratio of 13.36 compared to PFE's 8.2, indicating a more expensive valuation for NVO [28]

Core Insights - Pfizer and AbbVie are both leading U.S. pharmaceutical companies with strong positions in various therapeutic areas, with Pfizer's oncology sales accounting for approximately 28% of its total revenues and AbbVie’s immunology drugs contributing around 50% of its net revenues [1][2]. Pfizer (PFE) Overview - Pfizer has strengthened its oncology position with the acquisition of Seagen in 2023, leading to a 7% increase in oncology revenues year-to-date, driven by key drugs [4]. - Non-COVID operational revenues are improving, with a 9% operational increase in recently launched and acquired products in the first nine months of 2025, supporting growth expectations for 2026 [5]. - Pfizer anticipates cost savings of $7.7 billion by the end of 2027 through restructuring and cost reduction efforts, with a dividend yield of around 7% [6]. - The company is expanding its pipeline through acquisitions, including a $10 billion deal for Metsera, which adds significant potential in the obesity market [7]. - Pfizer faces challenges with declining sales of COVID products and expects a significant impact from patent expirations between 2026-2030, estimating a $1 billion unfavorable impact from the Inflation Reduction Act [8][10]. AbbVie (ABBV) Overview - AbbVie has successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [11][12]. - The oncology segment contributed $5.0 billion in revenues, while neuroscience drugs saw a 20.3% increase in sales, totaling almost $7.8 billion [13]. - AbbVie has pursued inorganic growth through over 30 M&A transactions since early 2024, particularly in immunology, while facing near-term challenges from Humira's biosimilars and competitive pressures [14]. - The aesthetics portfolio has seen a 7.4% decline in global sales, impacted by macroeconomic challenges and low consumer sentiment [15]. Financial Estimates and Performance - The Zacks Consensus Estimate for Pfizer's 2025 sales implies a 1.1% decrease, while AbbVie's estimates indicate an 8.1% increase in sales [16]. - Year-to-date, Pfizer's stock has declined by 3.0%, whereas AbbVie's stock has risen by 30.5%, outperforming the industry average of 15.9% [20]. - AbbVie’s dividend yield is 2.8%, compared to Pfizer’s 6.7% [26]. Investment Outlook - Both companies hold a Zacks Rank 3 (Hold), but AbbVie is favored due to its robust growth prospects and lack of significant upcoming loss of exclusivity events [28]. - AbbVie expects to achieve mid-single-digit revenue growth in 2025, driven by the strong performance of Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29].

Core Viewpoint - The healthcare sector presents significant investment opportunities for long-term investors, particularly in stocks that demonstrate growth potential and resilience against market fluctuations [2]. Group 1: Pfizer - Pfizer has experienced a transformative period, shifting from slow growth to a surge in revenue due to the success of its COVID-19 vaccine developed with BioNTech [4]. - The company has strategically utilized profits from its COVID-19 products to acquire other firms, including a pivotal $43 billion acquisition of Seagen in 2023, enhancing its oncology portfolio with four approved cancer therapies [5][6]. - Pfizer's recent product launches include a range of treatments such as the RSV vaccine Abrysvo and the migraine treatment Nurtec, which are expected to drive future growth [7]. - The company reported total revenue of approximately $45 billion in the first nine months of 2025, with a 24% year-over-year increase in GAAP net income to $9.4 billion [10]. - Pfizer has a strong dividend history, delivering over $7 billion in cash dividends in the first nine months of 2025, with a current yield close to 7% [11]. - The company is focusing on non-COVID growth areas, including oncology and cardiometabolic treatments, while also pursuing acquisitions to counteract patent expirations [9][12]. Group 2: Viking Therapeutics - Viking Therapeutics is a clinical-stage biopharmaceutical company with its value largely dependent on successful clinical trials and regulatory approvals [13]. - The lead candidate, VK2735, has shown promising results in early trials for weight loss and diabetes improvement, targeting both GLP-1 and GIP receptors [14][15]. - The injectable formulation of VK2735 is in phase 3 trials and has demonstrated significant weight reduction, positioning it competitively against existing treatments [17]. - Viking has a diversified pipeline, including candidates for metabolic liver disease and a rare genetic condition, which may reduce reliance on a single product's success [18][19]. - The company ended Q3 2025 with over $715 million in cash, providing stability for ongoing research and development without immediate fundraising concerns [19][20].

Group 1: Pfizer's Growth Strategy - The acquisition of Seagen for $43 billion in 2023 is crucial for Pfizer's growth strategy to address patent losses and transition from the pandemic era, significantly enhancing its cancer drug portfolio and pipeline [1] - Pfizer has over 100 drug candidates in development, with 28 in late-stage trials, focusing on oncology and immunology, as it faces patent cliffs on key blockbuster drugs between 2026 and 2028 [2] - Pfizer's oncology revenue grew by 9% in the first half of 2025, with key products like Xtandi, Lorbrena, and Padcev driving growth [8] Group 2: Financial Performance - Pfizer returned $4.9 billion to shareholders through dividends in the first half of 2025 and generated free cash flow of about $16 billion over the trailing 12 months [3] - The company's stock has become relatively cheap compared to historical levels, with a dividend yield exceeding 7%, significantly higher than the S&P 500 average and most healthcare peers [4] - Pfizer reported $28.4 billion in revenue in the first half of 2025, with recently launched and acquired products contributing about $5 billion, reflecting a 15% operational increase compared to the previous year [9] Group 3: Recent Acquisitions and Market Position - Pfizer is in an acquisitive phase, recently acquiring Metsera for $10 billion, targeting the GLP-1 weight loss drug market, despite competition from Novo Nordisk [10] - The company aims to maximize the performance of its non-COVID products, which are expected to generate approximately $20 billion in revenue by 2030 [8] - Pfizer's strategic focus on a robust product pipeline and discounted valuation may present an attractive buy-and-hold opportunity for value investors [11] Group 4: Market Dynamics - Healthcare stocks, including Pfizer, can be temporarily undervalued, presenting opportunities for value investors to acquire shares at favorable levels [5] - Many healthcare companies operate in stable industries with strong balance sheets and cash flows, making them attractive to value investors [6]